RxDoctor Payments Data

Jeffrey Kulik, MD

Allergy & Immunology · Elmhurst, ILNPI 1134219942

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $23,575 of the $28,479 with a category attached, or 82.8%. Novartis accounts for 82.2% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $23,158 and has fallen 97.0% since, to $686 in 2025.

$28,479in general payments, 2019–2025

Across 127 payments — averaging $224.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$23K
  • Genentech USA, Inc.$4K
  • GSK$252
  • AstraZeneca$201
  • Amgen$72
  • Pfizer$72
  • plus $420 from 12 others

What the payments were for

  • Speaking & faculty fees$23,57583%
  • Travel & lodging$2,0497%
  • Food & beverage$2,85510%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,479 in reported general payments places this provider in the 85th percentile of 161 allergy & immunology providers in Illinois.

See all allergy & immunology providers in Illinois

Medicare billing

Part B allowed, 2024
$55,171
Medicare patients
175
Services billed
3,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab15$80,839
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$26,364
Advair HfaFluticasone Propion/Salmeterol20$7,897
SymbicortBudesonide/Formoterol Fumarate14$6,704
Levocetirizine Dihydrochloride354$6,454
Azelastine Hcl116$4,264
Epinephrine23$4,082
Azelastine-FluticasoneAzelastine/Fluticasone12$3,082
Montelukast Sodium259$3,070
Albuterol Sulfate HfaAlbuterol Sulfate48$1,673
Fluticasone Propionate78$1,408
Ipratropium Bromide34$1,313
Methylprednisolone14$104
Triamcinolone Acetonide21$103
Prednisone12$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$252$26,36421 claims
AstraZenecaSymbicort$201$6,70414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 161 allergy & immunology providers in Illinois.

Other allergy & immunology in Elmhurst

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →